Inherited and acquired changes in pre-mRNA processing have significant roles in human diseases, especially cancer. Characterization of aberrantly spliced mRNAs may thus contribute to understand malignant transformation. We recently reported an anti-oncogenic potential for the SOX9 transcription factor in the colon. For instance, the Sox9 gene knock out in the mouse intestine results in an excess of proliferation with appearance of hyperplasia. SOX9 is expressed in colon cancer cells but its endogenous activity is weak. We looked for SOX9 variants that may impair SOX9 activity in colon cancer cells and we discovered MiniSOX9, a truncated version of SOX9 devoid of transactivation domain as a result of retention of the second intron. A significant overexpression of MiniSOX9 mRNA in human tumor samples compared with their matched normal tissues was observed by realtime reverse transcriptase-PCR. Immunohistochemistry revealed that MiniSOX9 is expressed at high levels in human colon cancer samples whereas it is undetectable in the surrounding healthy tissues. Finally, we discovered that MiniSOX9 behaves as a SOX9 inhibitor, inhibits protein kinase Ca promoter activity and stimulates the canonical Wnt pathway. This potential oncogenic activity of the SOX9 locus gives new insights on its role in colon cancer.
Inherited and acquired changes in pre-mRNA processing have significant roles in human diseases, especially cancer. Characterization of aberrantly spliced mRNAs may thus contribute to understand malignant transformation. We recently reported an anti-oncogenic potential for the SOX9 transcription factor in the colon. For instance, the Sox9 gene knock out in the mouse intestine results in an excess of proliferation with appearance of hyperplasia. SOX9 is expressed in colon cancer cells but its endogenous activity is weak. We looked for SOX9 variants that may impair SOX9 activity in colon cancer cells and we discovered MiniSOX9, a truncated version of SOX9 devoid of transactivation domain as a result of retention of the second intron. A significant overexpression of MiniSOX9 mRNA in human tumor samples compared with their matched normal tissues was observed by realtime reverse transcriptase-PCR. Immunohistochemistry revealed that MiniSOX9 is expressed at high levels in human colon cancer samples whereas it is undetectable in the surrounding healthy tissues. Finally, we discovered that MiniSOX9 behaves as a SOX9 inhibitor, inhibits protein kinase Ca promoter activity and stimulates the canonical Wnt pathway. This potential oncogenic activityIntroduction Sex-determining region Y-box transcription factors (SOX) belong to the high mobility group superfamily, made of 20 members in mammals. SOX proteins control gene transcription by bending DNA through interaction of their high mobility group domain to the minor groove of the DNA helix at the consensus response sequence (A/T)(A/T)CAA(A/T)G (Kamachi et al., 2000) . SOX members are conserved across species and are involved in a number of developmental processes. Heterozygous mutations of the SOX9 gene are responsible for campomelic dysplasia (Foster et al., 1994) , an autosomal dominant disorder resulting in skeletal and developmental abnormalities and in frequent neonatal death because of respiratory deficiencies (Houston et al., 1983) . SOX9 was then shown to be a key regulator of chondrogenesis (Akiyama et al., 2002) , neurogenesis (Stolt et al., 2003) , male sex determination (Chaboissier et al., 2004) , neural crest development (Cheung et al., 2005) and biliary development (Antoniou et al., 2009) . SOX9 is overexpressed in tumors from many origins and particularly in colon (Blache et al., 2004; Jay et al., 2005) , but its role in cancer appears mostly antioncogenic. SOX9 is a canonical Wnt/b-catenin response gene (Blache et al., 2004 ) that exerts a negative feedback control on this pathway in colon cells (Bastide et al., 2007) . Moreover, SOX9 directly upregulates the tumor suppressor CEACAM1 (CarcinoEmbryonic Antigenrelated Cell Adhesion Molecule 1) in the intestine epithelium , while it downregulates the carcinoembryonic antigen (CEA or CEACAM5) in human colon carcinoma cells (Jay et al., 2005) . SOX9 also increases apoptosis in colon tumor cells (Jay et al., 2005) and reduces cell proliferation rate, as illustrated by hyperplasia and dysplasia induced by Sox9 abrogation in the intestine epithelium (Bastide et al., 2007; Zalzali et al., 2008) . The anti-proliferative activity of SOX9 was also evidenced in retinoid-treated breast cancer cell lines and melanomas (Afonja et al., 2002; Passeron et al., 2009; Muller et al., 2010) . Finally, loss of SOX9 expression and promoter hypermethylation is associated with bladder cancer progression (Aleman et al., 2008) . Thus, even if SOX9 is potentially oncogenic through PKCa repression in the intestine epithelium (Dupasquier et al., 2009) , most data support the notion that SOX9 displays an overall anti-oncogenic activity. In agreement with the weak DNA-binding-dependent activity of endogenous SOX9 in colon cancer cells (Darido et al., 2008) , SOX9 overexpression in colon tumors therefore appears paradoxical, unless its antioncogenic activity cannot be exerted. In this study, we report the discovery of MiniSOX9, a truncated SOX9 variant highly expressed in colon tumors that behaves as a SOX9 inhibitor and Wnt/b-catenin signaling pathway activator.
Results

SOX9 mRNA variants are expressed in colon cancer cells
Multiple heterozygous mutations affect the SOX9 gene in campomelic dysplasia samples, some of which led to the expression of truncated SOX9 variants lacking the transactivation domain and displaying a dominant negative activity (Giordano et al., 2001) . As SOX9 deleted of its transactivation domain represses wild-type SOX9 activity in colon cancer cells (Blache et al., 2004; Bastide et al., 2007; Zalzali et al., 2008) , we reasoned that such variants may well be expressed in colon cancer cells. We thus looked for a SOX9 splice variant resulting in a protein without the transactivation domain encoded by exon3. DNAseI-treated total RNAs were reverse transcribed using oligo-dT primers and complementary DNAs were amplified by PCR using primer sets that discriminate fully spliced SOX9 mRNA from species containing the 5 0 end of intron2 ( Figure 1a ). Fully spliced SOX9 mRNA was detected in all samples, as expected. A PCR product corresponding to partially spliced SOX9 mRNAs named as MiniSOX9 was found in all human colon tumor cell lines and samples examined, whereas it was nearly undetectable in normal colon. Real-time reverse transcriptase (RT)-PCR also indicated that SOX9 and MiniSOX9 mRNAs were present in all human colon tumor cell lines tested with a higher amount of MiniSOX9 mRNA in DLD1 cells (Figures 1b and c) . The presence of differentially spliced SOX9 mRNA species was supported by northern blot experiments: exon1, intron2 or exon3 antisense RNA probes revealed the existence of four major mRNA species (Figure 1d) . One hybridized to exon1 and exon3 but not to intron2 probes and thus corresponded to the fully spliced SOX9 mRNA (black bar). We also observed mRNA species larger than the fully spliced mRNA (solid arrowhead). This larger mRNA form is long enough to contain the whole intron2 and is only detectable in DLD1 cells likely due to higher amounts of mRNAs (Figure 1d ). RT-PCR using combinations of a unique forward primer anchored in exon1 and various reverse primers spanning over intron2 amplified DNA fragments of the expected sizes in the three HT29Cl16E, SW480, DLD1 cell lines, suggesting that the whole intron2 is retained (Figure 1e ). DNA sequencing of the PCR fragments confirmed the retention of whole of the intron2. Northern blots also unveiled two mRNA species shorter than the fully spliced SOX9 mRNA. One (empty arrowhead) may result from non canonical splicing sites (Agrawal et al., 2009) . The shortest mRNA species that hybridized to exon1, intron2 but not to exon3 indicated the use of an alternative polyadenylation site. According to Retelska et al. (2006) , 46.73% polyadenylation events are dependent on the AAUAAA canonical polyadenylation signal (PAS) but 37.08% of them also occur in the presence of infrequently used PAS including GAUAAA (1.64%). As we found a conserved 'GATAAA' motif in mammals (Figure 1f and Supplementary Figure S1 ) as well as TGTA, TATA, G-rich and C-rich polyadenylation regulatory elements in intron2 (Gilmartin 2005; Hu et al., 2005; Lee et al., 2008) we performed 3 0 RACE PCR on polyA-mRNA from DLD1 cells, which confirmed the existence of SOX9 mRNA ended by a polyA tract located 409-bp downstream of the exon2 border ( Figure 1f and Supplementary Figure S1 ). Our data therefore evidence that colon cancer cell lines express distinct SOX9 mRNA species, generated through intron2 retention and the use of two polyadenylation signals.
Retention of SOX9 intron2 leads to a truncated protein: MiniSOX9 The retention of the intron2 is predicted to generate a translated peptide termed as MiniSOX9 because a premature stop codon is located 228 nucleotides downstream of the exon2 border. This putative protein still contains the high mobility group domain but is devoid of the trans-activating domain ( Figure 2a ). To investigate whether MiniSOX9 is expressed in colon tumor cell lines known to express SOX9 we used two different antibodies ( Figure 2a) . Using an N-terminal pan-SOX9 antibody (Notarnicola et al., 2006) , both SOX9 (56 kDa) and MiniSOX9 (33.5 kDa) were detected in all the colon tumor cell lines (Figure 2b ). Using the MiniSOX9-specific antibody (Figure 2a ), a single band was detected in SW480, HT29Cl.16E and DLD1 cells ( Figure 2c ) as well as in the human ovarian carcinoma BG1 and Cov434 cell lines, respectively derived from stage II ovarian epithelial adenocarcinoma (Geisinger et al., 1989) and primary granulosa (Zhang et al., 2000) and in the pluripotent human testicular embryonal carcinoma cell line NT2/D1 previously shown to express SOX9 (Figure 2c ). To confirm that the detected protein is MiniSOX9, we immunoprecipitated SW480, HT29Cl.16E and DLD1 cell extracts with the anti-Nterminal pan-SOX9 antibody (Notarnicola et al., 2006) . Western blotting analysis of immunoprecipitates with the anti-MiniSOX9 antibody detected a single 33.5 kDa band ( Figure 2d , upper panel). Conversely, after MiniSOX9 immunoprecipitation, the same 33.5 kDa band was observed with the anti-N-terminal pan-SOX9 antibody (Figure 2d , lower panel). Finally, we examined the subcellular localizations of SOX9 and MiniSOX9 in DLD1 cells (Figure 2e ). Immunofluorescence specific to either SOX9 or MiniSOX9 predominantly accumulated in the nucleus, suggesting that MiniSOX9 is potentially able to regulate gene transcription. Similar observations were made in HT29Cl.16E and SW480 cells (not shown).
MiniSOX9 inhibits SOX9 activity, inhibits PKCa promoter activity and stimulates the Wnt/bcatenin pathway by interacting with b-catenin We previously showed that a truncated SOX9 protein (SOX9DC) lacking the transactivation domain inhibited the DNA-binding-dependent SOX9 activity and activated the canonical Wnt pathway (Blache et al., 2004; Jay et al., 2005; Bastide et al., 2007) . To examine if MiniSOX9 behaves as SOX9DC, we first addressed the impact of MiniSOX9 on SOX9 activity using a reporter MiniSOX9 in colon tumor R Abdel-Samad et al construct in which luciferase expression is driven by SOX-binding sites (Jay et al., 2005) . SOX9 overexpression elicited an increased luciferase activity, which was significantly repressed in the presence of MiniSOX9 (Figure 3a) . We next used the TOPFLASH reporter system to monitor activation of the canonical Wnt pathway in DLD1 cells. MiniSOX9 upregulated the Wnt/b-catenin-dependent transcriptional activity, whereas SOX9 repressed it (Figure 3b ). This upregulation was associated with b-catenin accumulation in the nuclei of DLD1 cells overexpressing MiniSOX9 (Figure 3c and Supplementary Figure S2) . In HEK293 cells that do not express SOX9, the Wnt/b-catenin was also activated by MiniSOX9 on expression of a It has been recently shown that the N-terminal moiety of SOX9 promotes the nuclear localization of b-catenin whereas the C-terminal region of SOX9 is responsible of the inhibition of the b-catenin transcriptional activity (Topol et al., 2009) . By co-immunoprecipitation, we confirmed the physical interaction of SOX9 with b-catenin (Figure 3e) . The same investigators also showed that SOX9DC binds to b-catenin and promotes its nuclear localization and that the absence of the SOX9 C-terminal region in SOX9DC resulted in an activation of the Wnt/bcatenin signaling pathways. As MiniSOX9 does not possess the SOX9 C-terminal region it should behave like SOX9DC. Here, we show that indeed MiniSOX9 activates the Wnt signaling pathway (Figures 3b and d) , promotes b-catenin nuclear localization ( Figure 3c ) and physically interacts with b-catenin (Figure 3e) .
Finally, we examined the effect of MiniSOX9 on PKCa expression, shown to be repressed by SOX9 through interactions of its central region with the SP1 transcription factor, (Dupasquier et al., 2009) . We evidenced that MiniSOX9 inhibited PKCa promoter activity to the same extent as SOX9 (Figure 3f ). Taken together, these observations indicate that MiniSOX9 can activate canonical Wnt target genes and represses PKCa, two features in favor of oncogenic properties.
MiniSOX9 is expressed in intestinal tumors of APCD14 mice As mentioned earlier, the presence of a stop codon followed by a polyadenylation signal is a conserved feature of SOX9 intron2 in mammals (Figure 1c) . We thus searched for the presence of MiniSOX9 in mice. APC(D14/ þ ) mice express a deleted APC similar to the one responsible for human familial adenomatous polyposis and sporadic colon cancers and develop spontaneous intestine adenomas as a consequence of a constitutively activated Wnt/b-catenin pathway (Colnot et al., 2004) . By RT-PCR, we searched for the presence of MiniSOX9 mRNAs in four adenomas and adjacent non-tumor intestinal tissues from APC(D14/ þ ) mice (Figure 4a ). PCR products predictive for MiniSOX9 expression were readily detected in three of four tumors but were hardly detected in adjacent non-tumor tissues or in the intestine of wild-type mice. All cases (increases, decreases or no changes) were observed when comparing SOX9 mRNA levels in adenomas versus their adjacent control tissues. DNA sequencing of PCR products confirmed that MiniSOX9 expression is not restricted to human cancer cells and is also expressed in mice. Additional real-time RT-PCR analysis, on a limited number of adenomas and their corresponding adjacent tissues from APC (D14/ þ ) mice, did not show any significant increase in MiniSOX9 in adenomas even when the median value was higher. On the other hand, SOX9 was significantly increased in adenomas (Supplementary Figure S3) .
MiniSOX9 is highly expressed in human colon adenocarcinomas
In order to compare MiniSOX9 expression in human colon tumors with their adjacent normal tissues, we performed a real-time quantitative RT-PCR analysis. As shown in Figure 4b , MiniSOX9 is significantly overexpressed in human colon tumors (n ¼ 17). As expected, SOX9 is also overexpressed in human colon tumors, (Figure 4c ) (n ¼ 27). Distinct stages of tumor node metastasis (TNM) classification of human tumors were analyzed (see Materials and methods section) and no obvious relationship between the stage and SOX9 or MiniSOX9 expression was observed. Immunohistochemistry experiments using the anti-Nter pan-SOX9 antibody and the anti-Cter MiniSOX9 antibody showed that MiniSOX9 was almost undetectable in the human healthy colon epithelium adjacent to tumors (Figure 5b ), whereas the pan-SOX9 signal was restricted to cells proliferating at the bottom half of the crypts (Figure 5a ), as previously reported (Blache et al., 2004) . By contrast, tumors were intensely stained either with the N-ter pan-SOX9 (Figure 5c ) or with the MiniSOX9-specific antibodies (Figure 5d ), indicating that MiniSOX9 is highly expressed in tumors. Similar results were obtained with samples from another patient analyzed with the C-terminal SOX9 and MiniSOX9 antibodies (Figures 5e-h ). SOX9 was detected both in the healthy tissue (Figure 5e ) and the adjacent tumor (Figure 5g ) whereas MiniSOX9 undetectable in the healthy tissue (Figure 5f ) was strongly expressed in the adjacent tumor (Figure 5h ). High and preferential MiniSOX9 expression in colon tumors was further supported by analysis 
SOX9 gene mutations can favor MiniSOX9 expression
Since MiniSOX9 results from intron2 retention, we looked for mutations that might qualitatively affect the splicing of SOX9 in colon cancer cell lines. Analysis of MiniSOX9 transcripts detected an A/G mutation (GTGAAT instead of GTGAGT) within the splicing donor site of intron2, present at the heterozygous state in the DLD1 genome. The incidence of this mutation on the splicing efficiency was assessed with minigene constructs made of 5 0 flag-tagged SOX9 exon2, intron2
with either the wild-type or mutant splicing donor site and exon3. These constructs were transfected in HEK293 cells (Figure 7 ) where SOX9 and MiniSOX9 are normally not expressed. The minigene containing a wild-type donor site (GTGAGT) produced a major antiflag positive 41 kDa protein, that is, the expected size of peptides translated from fully spliced RNAs. By contrast, the minigene carrying the mutated donor site (GTGAAT) produced an additional 19 kDa protein, corresponding to the sizes of peptides translated from mRNAs having retained intron2. The G to A substitution in the donor site thus substantially decreases efficiency of intron2 splicing, which might account for the high amount of unspliced SOX9 mRNA observed in MiniSOX9 in colon tumor R Abdel-Samad et al DLD1 cells (Figure 1a ). Such mutations were detected neither in other cell lines (HCT116, HT29Cl.16E, SW480, SW620, T84, BG1, Cov434 and NT2/D1) nor in APC(D14/ þ ) mice tumors.
Discussion
Alternative splicing represents a major mechanism for generating proteomic diversity because 95% of multiexon genes in the human genome are expected to produce alternatively spliced mRNAs (Chen and Manley, 2009) . It is also well admitted that a general reduction in splicing fidelity is a common feature of cancer cells and, whether it is a cause or a consequence of carcinogenesis is still unclear. Appearance of new mRNA variants might produce peptides that interfere with activity of the wild-type protein or even exert new biological functions relevant to carcinogenesis (Brinkman, 2004) . This study evidenced in colon cancer cells the expression of SOX9 mRNA species that have retained intron2 and are translated into MiniSOX9, a truncated SOX9 protein MiniSOX9 in colon tumor R Abdel-Samad et al lacking the C-terminal transactivation domain. Splice variants of SOX9 or any other SOX member had never been associated so far with cancer. Furthermore, we evidenced that MiniSOX9 accumulates in the nucleus, inhibits SOX9 DNA-binding-dependent transcriptional activity, inhibits PKCa expression and stimulates the canonical Wnt signaling pathway, known to activate in colon cancers. All these features call for an oncogenic role of MiniSOX9, because PKCa behaves as a tumor suppressor in the intestine epithelium (Pysz et al., 2009) and the tumor-promoting activity of Wnt/b-catenin is well documented (MacDonald et al., 2009) . How MiniSOX9, devoid of transactivation domain, can activate Wnt? It might be a consequence of SOX9 inhibition, because SOX9 upregulates ICAT (inhibitor of b-catenin and T-cell factor (TCF))/TCF interaction (Tago et al., 2000) and the Groucho-related corepressors TLE2-4 (Cavallo et al., 1998; Roose et al., 1998) in HT29Cl.16E cells (Bastide et al., 2007) , as well as CEACAM1 , which binds to the armadillo repeats of b-catenin, thereby inducing its redistribution from the cytosol to the plasma membrane (Jin et al., 2008; Leung et al., 2008) . Moreover, MiniSOX9 is able to activate the Wnt pathway on its own, through its capacity to bind to b-catenin and inducing b-catenin accumulation in the nucleus. Retention of SOX9 intron2 occurred in all tested colon tumor cell lines and samples. Since such splice variants were nearly undetectable in most human healthy tissues samples, this suggests that MiniSOX9 expression is a common feature shared by colon tumors. This is supported by our statistical analysis evidencing the overexpression of MiniSOX9 mRNA in human colon tumors (Figure 4b ). We also detected MiniSOX9 in ovary and testis cancer cell lines, raising the possibility that it might be expressed in many cancer types. The question remains open as to whether MiniSOX9 results from an unspecific splicing error or from reactivation of a physiologically relevant process. Its high incidence in tumors and the conservation of the splice donor site and polyadenylation signal in mammals favor the second hypothesis, suggesting that MiniSOX9 is produced in particular physiological conditions, for example, development or specific cell homeostasis. We cannot formally exclude that MiniSOX9 is expressed at low levels and/or in poorly represented cell types such as intestinal stem cells. In all instances, the high differential in MiniSOX9 expression between tumoral and adjacent healthy tissues makes this variant a new and promising colon cancer cell biomarker. We found an intron2 variant donor splice site of intron2 in DLD1 cells, which led to significantly higher MiniSOX9 mRNA amounts (Figure 1c) . However, the levels of MiniSOX9 protein in DLD1 were not higher than in other cell lines (Figures  2b and c) . This variation of sequence might be a singlenucleotide polymorphism but was not found in any of the available data banks. Further studies are needed to evaluate the frequency of such mutations in human tumors and their correlation with tumor incidence.
Finally, this study points to the critical issue as to unambiguously identify the exact nature of the proteins expressed in particular situations. Indeed, a significant fraction of data pertaining to SOX9 expression in biological systems relied on experimental procedures that could not distinguish SOX9 from MiniSOX9 and might have drawn misleading conclusions given the diametrically opposed effects of these two proteins on cell properties.
Materials and methods
Tissues and cell cultures
Human tissue sections were provided by Dr Christine Pignodel on patients agreement (Service d'Anatomie et Cytologie Pathologiques, CHU Nıˆmes, France). Specimens of colon biopsies were obtained from the pathologist after resection according to French government regulations and with approval of the ethical committee (Nıˆmes Hospital). Informed consent was obtained from all patients. Tissue samples were stored in liquid nitrogen until further use. Human colon cancer cells were cultured as previously described (Blache et al., 2004) .
Plasmids
Luciferase reporters such as the SOX-luciferase, PKCa promoter (À227 to þ 77)-luciferase and TCF-luciferase were previously described Jay et al., 2005; Dupasquier et al., 2009) . Minigenes were obtained by PCR amplification of a sequence spanning the wild-type or mutated human SOX9 gene exon2-intron2-exon3 and were subcloned in frame (5 0 end) with a flag epitope sequence in the pcDNA3 vector (Invitrogen, Cergy Pontoise, France). The flag-MiniS-OX9 construct was obtained from an RT-PCR product subcloned in frame (5 0 end) with a flag epitope sequence in the pcDNA3 vector. Other plasmids were previously described (Blache et al., 2004) .
RNA extraction, RT-PCR, real-time RT-PCR, northern blot and 3 0 RACE PCR Total RNAs were prepared using the RNeasy minikit (Qiagen, Courtaboeuf, France) and treated with RNase-free DNase I. Additional purifications of polyA þ RNA were performed on oligo-dT columns for northern blot analysis and 3 0 RACE PCR. Complementary DNA was all produced using oligo-dT primers. RNA from human colon biopsy was prepared using MagNA Pure LC 2.0 System (Roche Diagnostic, Meylan, France). RNA quantity and quality of samples were determined by the 260:280 nm absorbance ratios using a NanoDrop spectrophotometer (Thermo Fisher Scientific, Illkirch, France). For real-time PCR quantification of SOX9 and MiniSOX9 expression, absolute copy number for each mRNA was normalized to absolute b-actin mRNA copy number, using standard calibration curves. All primers used for classical and real-time RT-PCR are described in Supplementary table S4. Northern blot probes were in vitro transcribed using PCR amplified SOX9 gene exon1, intron2 and exon3 sequences subcloned in the PCR2 TA cloning vector (Invitrogen). Forward 5 0 -AGCAGGAGAAGGGCCTGT-3 0 and reverse 5 0 -GTACTGGTCCGCGAGCTTC-3 0 , forward 5 0 -ACCCCAC CGGACAAGCTAT-3 0 and reverse 5 0 -GGGTCCGGAAGAC CTAATTG-3 0 , forward 5 0 -ATCAAGACGGAGCAGCTGA G-3 0 and reverse 5 0 -CAAGGTCGAGTGAGCTGTGTG-3 0 primers couples were respectively used to amplify the exon1, intron2 and exon3 DNA sequences. 3 0 RACE PCR was performed using the 5 0 /3 0 Race PCR Kit second-generation kit from Roche Diagnostic. The first-strand complementary DNA was synthesized using an OligodTanchor primer and a SP1 primer (5 0 CCACCGGACAAG CTATCTCCG3 0 ) annealing within the 5 0 terminal end of intron 2. The resulting PCR product was further amplified by nested PCR using the OligodT-anchor primer and a SP2 primer (5 0 CTGGGAGATTCTTCGTGGGGAC3 0 ) annealing downstream the 'SP1' sequence.
Luciferase assays
Assays were performed in triplicate, at least three independent times as in (Blache et al., 2004) . Transfection efficiencies were normalized by co-transfecting the phRG-TK standardization vector (Promega, Charbonnie`res-les-Bains, France).
Antibodies
The MiniSOX9 antibody was raised using a standard rabbit immunization procedure with a synthetic peptide (GDSSWGLYASREGHTC). The antibody was purified from the rabbit serum by affinity with the synthetic peptide. The previously described C-terminal SOX9 antibody was used for immunofluorescence (Blache et al., 2004 ) and the C-terminal SOX9 antibody from Chemicon (Hants, UK) was used for immunochemistry. The N-terminal pan-SOX9 antibody (Notarnicola et al., 2006) was previously described. The b-catenin antibody was from BD Bioscience (Le Pont-De-Claix, France). Mouse and rabbit anti-flag and mouse anti-b-actin antibodies were from Sigma-Aldrich (Lyon, France).
Immunoprecipitation
Immunoprecipitation were performed with Protein G PLUSagarose beads (Santa Cruz, Heidelberg, Germany), according to the manufacturer's recommendations. For b-catenin coimmunoprecipiatation, HEK293 cells were transfected with flag-SOX9 or flag-MiniSOX9 together with b-catenin. Immunoprecipitations were performed with the flag antibody or the mouse IgG mouse (Milipore, Molsheim, France) as control. Immunoprecipited proteins were analyzed by western blot using the anti-b-catenin antibody.
Immunofluorescence, immunohistochemistry and western blot For immunofluorescence, DLD1 cells were plated in 24-well plates (50 000 cells/well) on coverslips. Cy3-conjugated secondary, A488-conjugated anti-rabbit secondary antibodies and the Cy3-conjugated anti-mouse secondary antibody were from Santa Cruz. Preparations were mounted in Mowiol and observed using an epifluorescent microscope (Zeiss, Le Pecq, France). Immunohistochemistry was performed as previously described (Bastide et al., 2007) . Staining was developed with diaminobenzidine (DAB) (brown precipitate) and a hematoxylin counterstain was used, after dehydration, sections were mounted in Pertex (Histolab, Gothenburg, Sweden). Immunohistochemistry images were acquired using an Eclipse 80i microscope (Nikon, Kingston, UK). For western blotting, an equal amount of protein, measured by the Bradford assay, was loaded on each lane of the gel. Proteins were visualized using Chemiluminescence Blotting Substrate (Roche Diagnostic). 
